UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Clinical manifestations, evaluation, and staging of renal cell carcinoma

Author
Michael B Atkins, MD
Section Editor
Jerome P Richie, MD, FACS
Deputy Editor
Michael E Ross, MD

INTRODUCTION

Malignant neoplasms involving the kidney may be primary or secondary tumors. Secondary renal neoplasms are usually clinically insignificant and discovered at postmortem examination.

Renal cell carcinomas (RCCs), which originate within the renal cortex, constitute 80 to 85 percent of primary renal neoplasms. Transitional cell carcinomas of the renal pelvis are the next most common (approximately 8 percent). Other parenchymal epithelial tumors, such as oncocytomas, collecting duct tumors, and renal sarcomas, are rare. Nephroblastoma or Wilms' tumor is common in children (5 to 6 percent of all primary renal tumors). (See "Epidemiology, pathology, and pathogenesis of renal cell carcinoma" and "Malignancies of the renal pelvis and ureter".)

The clinical and radiographic presentation of RCC and the methods used for tumor staging, as well as their potential application for screening, will be reviewed here. The prognosis and treatment of RCC are discussed separately. (See "Prognostic factors in patients with renal cell carcinoma".)

CLINICAL MANIFESTATIONS

Patients with renal cell carcinoma (RCC) can present with a range of symptoms; unfortunately, many patients are asymptomatic until the disease is advanced. At presentation, approximately 25 percent of individuals either have distant metastases or advanced locoregional disease [1].

Patients with localized disease can present with a wide array of symptoms and/or laboratory abnormalities, or they may be diagnosed incidentally. In a 1971 review of 309 consecutive patients with RCC, the most common presenting symptoms were hematuria, abdominal mass, pain, and weight loss [2]. In contemporary series, fewer patients have the typical symptoms and there is an increased frequency of incidental diagnosis due to radiologic procedures performed for other indications. (See "Epidemiology, pathology, and pathogenesis of renal cell carcinoma", section on 'Epidemiology'.)

                     

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Tue Aug 02 00:00:00 GMT 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Garnick MB. Primary neoplasms of the kidney. In: Therapy in Nephrology and Hypertension: A Companion to Brenner and Rector's the Kidney, Brady HR, Wilcox CS (Eds), WB Saunders, Philadelphia 1998.
  2. Skinner DG, Colvin RB, Vermillion CD, et al. Diagnosis and management of renal cell carcinoma. A clinical and pathologic study of 309 cases. Cancer 1971; 28:1165.
  3. Gudbjartsson T, Thoroddsen A, Petursdottir V, et al. Effect of incidental detection for survival of patients with renal cell carcinoma: results of population-based study of 701 patients. Urology 2005; 66:1186.
  4. DeKernion JB. Real numbers. In: Campbell's Urology, Walsh PC, Gittes RF, Perlmutter AD (Eds), WB Saunders, Philadelphia 1986. p.1294.
  5. Gibbons RP, Monte JE, Correa RJ Jr, Mason JT. Manifestations of renal cell carcinoma. Urology 1976; 8:201.
  6. PINALS RS, KRANE SM. Medical aspects of renal carcinoma. Postgrad Med J 1962; 38:507.
  7. Chisholm GD, Roy RR. The systemic effects of malignant renal tumours. Br J Urol 1971; 43:687.
  8. Laski ME, Vugrin D. Paraneoplastic syndromes in hypernephroma. Semin Nephrol 1987; 7:123.
  9. Gold PJ, Fefer A, Thompson JA. Paraneoplastic manifestations of renal cell carcinoma. Semin Urol Oncol 1996; 14:216.
  10. Cherukuri SV, Johenning PW, Ram MD. Systemic effects of hypernephroma. Urology 1977; 10:93.
  11. Sufrin G, Mirand EA, Moore RH, et al. Hormones in renal cancer. J Urol 1977; 117:433.
  12. Walsh PN, Kissane JM. Nonmetastatic hypernephroma with reversible hepatic dysfunction. Arch Intern Med 1968; 122:214.
  13. Utz DC, Warren MM, Gregg JA, et al. Reversible hepatic dysfunction associated with hypernephroma. Mayo Clin Proc 1970; 45:161.
  14. Chuang YC, Lin AT, Chen KK, et al. Paraneoplastic elevation of serum alkaline phosphatase in renal cell carcinoma: incidence and implication on prognosis. J Urol 1997; 158:1684.
  15. Boxer RJ, Waisman J, Lieber MM, et al. Non-metastatic hepatic dysfunction associated with renal carcinoma. J Urol 1978; 119:468.
  16. Chang SY, Yu DS, Sherwood ER, et al. Inhibitory effects of suramin on a human renal cell carcinoma line, causing nephrogenic hepatic dysfunction. J Urol 1992; 147:1147.
  17. Blay JY, Rossi JF, Wijdenes J, et al. Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int J Cancer 1997; 72:424.
  18. Stadler WM, Richards JM, Vogelzang NJ. Serum interleukin-6 levels in metastatic renal cell cancer: correlation with survival but not an independent prognostic indicator. J Natl Cancer Inst 1992; 84:1835.
  19. Cranston WI, Luff RH, Owen D, Rawlins MD. Studies on the pathogenesis of fever in renal carcinoma. Clin Sci Mol Med 1973; 45:459.
  20. O'Grady AS, Morse LJ, Lee JB. Parathyroid hormone-secreting renal carcinoma associated with hypercalcemia and metabolic alkalosis. Ann Intern Med 1965; 63:858.
  21. LYTTON B, ROSOF B, EVANS JS. PARATHYROID HORMONE-LIKE ACTIVITY IN A RENAL CARCINOMA PRODUCING HYPERCALCEMIA. J Urol 1965; 93:127.
  22. GOLDBERG MF, TASHJIAN AH Jr, ORDER SE, DAMMIN GJ. RENAL ADENOCARCINOMA CONTAINING A PARATHYROID HORMONE-LIKE SUBSTANCE AND ASSOCIATED WITH MARKED HYPERCALCEMIA. Am J Med 1964; 36:805.
  23. Sandhu DP, Munson KW, Harrop JS, et al. Humoral hypercalcaemia in renal carcinoma due to parathyroid hormone related protein. Br J Urol 1993; 72:848.
  24. de la Mata J, Uy HL, Guise TA, et al. Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo. J Clin Invest 1995; 95:2846.
  25. Weissglas M, Schamhart D, Löwik C, et al. Hypercalcemia and cosecretion of interleukin-6 and parathyroid hormone related peptide by a human renal cell carcinoma implanted into nude mice. J Urol 1995; 153:854.
  26. Brereton HD, Halushka PV, Alexander RW, et al. Indomethacin-responsive hypercalcemia in a patient with renal-cell adenocarcinoma. N Engl J Med 1974; 291:83.
  27. Robertson RP, Baylink DJ, Marini BJ, Adkison HW. Elevated prostaglandins and suppressed parathyroid hormone associated with hypercalcemia and renal cell carcinoma. J Clin Endocrinol Metab 1975; 41:164.
  28. Da Silva JL, Lacombe C, Bruneval P, et al. Tumor cells are the site of erythropoietin synthesis in human renal cancers associated with polycythemia. Blood 1990; 75:577.
  29. Iliopoulos O, Levy AP, Jiang C, et al. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci U S A 1996; 93:10595.
  30. Wiesener MS, Seyfarth M, Warnecke C, et al. Paraneoplastic erythrocytosis associated with an inactivating point mutation of the von Hippel-Lindau gene in a renal cell carcinoma. Blood 2002; 99:3562.
  31. Pras M, Franklin EC, Shibolet S, Frangione B. Amyloidosis associated with renal cell carcinoma of the AA type. Am J Med 1982; 73:426.
  32. Chisholm GD. Nephrogenic ridge tumors and their syndromes. Ann N Y Acad Sci 1974; 230:403.
  33. Symbas NP, Townsend MF, El-Galley R, et al. Poor prognosis associated with thrombocytosis in patients with renal cell carcinoma. BJU Int 2000; 86:203.
  34. O'Keefe SC, Marshall FF, Issa MM, et al. Thrombocytosis is associated with a significant increase in the cancer specific death rate after radical nephrectomy. J Urol 2002; 168:1378.
  35. Sidhom OA, Basalaev M, Sigal LH. Renal cell carcinoma presenting as polymyalgia rheumatica. Resolution after nephrectomy. Arch Intern Med 1993; 153:2043.
  36. Sun MR, Ngo L, Genega EM, et al. Renal cell carcinoma: dynamic contrast-enhanced MR imaging for differentiation of tumor subtypes--correlation with pathologic findings. Radiology 2009; 250:793.
  37. Johnson CD, Dunnick NR, Cohan RH, Illescas FF. Renal adenocarcinoma: CT staging of 100 tumors. AJR Am J Roentgenol 1987; 148:59.
  38. Studer UE, Scherz S, Scheidegger J, et al. Enlargement of regional lymph nodes in renal cell carcinoma is often not due to metastases. J Urol 1990; 144:243.
  39. Nayak JG, Patel P, Saarela O, et al. Pathological Upstaging of Clinical T1 to Pathological T3a Renal Cell Carcinoma: A Multi-institutional Analysis of Short-term Outcomes. Urology 2016; 94:154.
  40. Koga S, Tsuda S, Nishikido M, et al. The diagnostic value of bone scan in patients with renal cell carcinoma. J Urol 2001; 166:2126.
  41. Semelka RC, Shoenut JP, Magro CM, et al. Renal cancer staging: comparison of contrast-enhanced CT and gadolinium-enhanced fat-suppressed spin-echo and gradient-echo MR imaging. J Magn Reson Imaging 1993; 3:597.
  42. Ramdave S, Thomas GW, Berlangieri SU, et al. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma. J Urol 2001; 166:825.
  43. Wu HC, Yen RF, Shen YY, et al. Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphate bone scan to detect bone metastases in patients with renal cell carcinomas - a preliminary report. J Cancer Res Clin Oncol 2002; 128:503.
  44. Goldberg MA, Mayo-Smith WW, Papanicolaou N, et al. FDG PET characterization of renal masses: preliminary experience. Clin Radiol 1997; 52:510.
  45. Bosniak MA, Birnbaum BA, Krinsky GA, Waisman J. Small renal parenchymal neoplasms: further observations on growth. Radiology 1995; 197:589.
  46. Dechet CB, Zincke H, Sebo TJ, et al. Prospective analysis of computerized tomography and needle biopsy with permanent sectioning to determine the nature of solid renal masses in adults. J Urol 2003; 169:71.
  47. Sánchez-Ortiz RF, Madsen LT, Bermejo CE, et al. A renal mass in the setting of a nonrenal malignancy: When is a renal tumor biopsy appropriate? Cancer 2004; 101:2195.
  48. Kidney. In: American Joint Committee on Cancer Staging Manual, Springer, New York 2009. p.447.
  49. Vogelzang NJ, Stadler WM. Kidney cancer. Lancet 1998; 352:1691.